A Study Of Oral Ozanimod As Induction Therapy For Moderately To Severely Active Crohn's Disease

Overview

About this study

The purpose of this study is to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults, age 18-75 years old.
  • Crohn's disease for ≥ 3 months on endoscopy and on histological exam.
  • Inadequate response or loss of response to corticosteroids, immunomodulators, and/or biologic therapy.
  • Patient has met each of the following 2 criteria:
    • Crohn's Disease Activity Index (CDAI) score ≥ 220 and ≤ 450;
    • Average daily stool frequency ≥ 4 points and/or an abdominal pain of ≥ 2 points.

Exclusion Criteria:

  • Diagnosis of ulcerative colitis, indeterminate colitis, radiation colitis, or ischemic colitis or known strictures or stenosis leading to symptoms of obstruction.
  • Current stoma, ileal-anal pouch anastomosis, symptomatic fistula, or need for ileostomy or colostomy.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Edward Loftus JR, M.D.

Closed for enrollment

Contact information:

IBD Clinical Research Unit

(507) 284-5908

More information

Publications

Publications are currently not available
.
CLS-20450955

Mayo Clinic Footer